|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
VDR KO did not alter Nos2 mRNA levels but significantly increased Arg1 mRNA levels in tumor M-MDSC by 100 %.
|
31783150 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, the location and type of Nos2<sup>high</sup> cells, NO flux, and the inflammatory status of other cells, such as Cox2<sup>high</sup> cells in the tumor niche contribute to Nos2 inflammatory mechanisms that promote disease progression of 4T1 tumors.
|
31683257 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This finding was accompanied with upregulated pro-inflammatory factors IL-6, TNFα, COX2 and NOS2 in tumors of Par2<sup>-/-</sup> mice.
|
31733286 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The effect of allergy on survival was significant (p = 0.025, HR 0.525, 95% CI 0.299-0.924), independent of the effect of chromosome 1p (p < 0.001, HR 93.4, 95% CI 16-546) and 19q (p = 0.801, HR 1.2, 95% CI 0.23-6.9) codeletion or TP53 mutation (p = 0.015, HR 2.7, 95% CI 1.2-5.9), unrelated to TERT expression (p = 0.365, HR 1.1, 95% CI 0.89-1.4) or ATRX mutation (p = 0.904, HR 1.04, 95% CI 0.51-2.14), independent of tumor grade (grade 2 versus grade 3, p = 0.004, HR 2.2, 95% CI 1.3-3.8), not independent of histology (oligodendroglioma and oligoastrocytoma, NOS versus astrocytoma, p = 0.08, HR 0.62, 95% CI 0.36-1.1).
|
30611004 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we identified the deleterious role of signaling via the type I interferon (IFN) receptor in tumor and antigen presenting cells, that induced the expression of nitric oxide synthase 2 (NOS2), associated with intratumor accumulation of regulatory T cells (Treg) and myeloid cells and acquired resistance to anti-PD-1 monoclonal antibody (mAb).
|
31481761 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Gene expression analysis in PDAC tumors (n = 63) showed a positive correlation between the expression of NOS2 and the tryptophan/kynurenine pathway genes, including indoleamine-2,3-dioxygenase 1 (IDO1) and several aryl hydrocarbon receptor (AHR)-target genes including NFE2L2 (NRF2), SERPINB2, IL1b, IL6 and IL8, which are implicated in pancreatic cancer.
|
31609478 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is becoming increasingly evident that nitric oxide synthase 2 (NOS2)-mediated NO/reactive nitrogen oxide species (RNS) are heavily involved in cancer progression and metastasis in different types of tumor.
|
29634348 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The relation of miR-19a expression to OS was further recognized by fixed model within the studies of sample size less than 150 (HRs = 1.68, CI: 1.35-2.08), NOS scores greater than or equal to 8 (HRs = 1.53, CI: 1.13-2.06) or less than 8 (HRs = 1.89, CI: 1.58-2.27), specimen derived from tumor (HRs = 1.73, CI: 1.42-2.12) or blood (HRs = 1.87, CI: 1.46-2.40) and the patients of osteosarcoma (HRs = 7.17, CI: 5.04-10.21).
|
31015372 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Transcriptomics analysis confirmed that in the lungs of tumour-bearing mice, stress significantly enriched pathways associated with tumourigenesis, some of which could be regulated with NOS inhibition.
|
31132432 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data also suggest functional interactions between cancerous T cells and tumor-infiltrating immune cells potentially relevant to PTCL-NOS pathogenesis.
|
30194138 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Both the pathogenesis and tumor biology in PTCL-NOS are poorly understood.
|
30291111 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The most common prognostic system for patients with PTCL-NOS, the PTCL-U score, is often inadequate because it does not take into consideration the role of host immunity or the microenvironment induced by the tumor.
|
30172956 |
2018 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We analyzed phospho-STAT3 (pSTAT3) expression in a cohort of 169 PTCL tumors and show overall 38% positivity with varied distribution among PTCL subtypes with 27% (16/59) in PTCL-NOS; 29% (11/38) in AITL, 57% (13/28) in ALK-negative ALCL, and 93% in ALK-pos ALCL (14/15), respectively.
|
30420593 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, white racial background with primary tumor sites in the brain overlapping and NOS areas seem to be associated with negative outcomes and decreased survival.
|
28951270 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To determine the NO signaling implication in tumor milieu, NO donor (Spermine NONOate (SPNO)), NOS inhibitor (L-nitro-L-arginine-methyl ester (L-NAME) and VEGF inhibitor (Avastin) were administrated to chick embryo vascular bed with and without HeLa cells.
|
29649432 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overall our results support that the level of inflammation at the tumor site regulates NOS2 expression by γδ T cells and the development of vitiligo associated melanoma.
|
30228955 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
NOS2 expressing tumors are sensitive to cisplatin chemotherapy, and NO may be used to sensitize cisplatin-resistant tumors to chemotherapy.
|
28326819 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low-dose irradiation or proinflammatory activation of macrophages in the tumor microenvironment may open options to boost NOS2 expression and activity and to initiate immunestimulatory features of NO that may help to restrict tumor growth.Antioxid.Redox Signal.26, 1023-1043.
|
27397579 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further study indicated that QRHX inhibited cancer-related inflammation in tumor by decreasing infiltration of TAMs and IL-6 and TNF-<i>α</i> production and meanwhile decreased arginase 1 (Arg-1) expression and increased inducible NO synthase (iNOS) expression.
|
28630636 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Inducible NO synthase (iNOS/NOS2) protein expression is a well-studied predictor of poor outcome in multiple cancers, and it has also been associated with inflammatory and immunosuppressive processes in the tumor microenvironment.
|
28121247 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Recent Advances: An increasing number of clinical studies have implicated a strong relationship between elevated tumor nitric oxide synthase-2 (NOS2) expression and poor patient survival.
|
27464521 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Subgroup analyses suggested that a high PLR predicted decreased OS in patient with BTC, regardless of sample size (<200 or ≥200), treatment methods (surgery, mixed, or chemotherapy), tumor stage (mixed or metastatic), analysis methods (univariate or multivariate), cut-off values (<150 or ≥150), and NOS score (<7 or ≥7).
|
28903023 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, iNOS gene therapy sensitized MDA-MB-231-luc-D3H1 tumors to docetaxel treatment.
|
28325291 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of the current study was to investigate the expression of Foxp3; IL10; TGFB1; IL17A; IL6 and NOS2 genes in tumor tissue, regional positive lymph nodes and distant metastasis obtained from 26 patients with advanced CRC.
|
28868572 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this interinstitutional study, we compared the expression of these markers and β-catenin in 11 cases each of SCT-NOS and S-SCT to determine if differences exist that could justify keeping a separate classification of these neoplasms.
|
28873352 |
2017 |